{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T06:55:04Z","timestamp":1776322504012,"version":"3.50.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T00:00:00Z","timestamp":1712534400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.clml.2024.03.003","type":"journal-article","created":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T03:03:36Z","timestamp":1710817416000},"page":"468-477","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Characteristics and Outcomes of Patients With Relapsed\/Refractory Multiple Myeloma After Exposure to Lenalidomide in First Line of Therapy: A Single Center Database Review in Greece"],"prefix":"10.1016","volume":"24","author":[{"given":"Efstathios","family":"Kastritis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6328-9783","authenticated-orcid":false,"given":"Ioannis","family":"Ntanasis-Stathopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Foteini","family":"Theodorakakou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalini","family":"Migkou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Roussou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panagiotis","family":"Malandrakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaos","family":"Kanellias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evangelos","family":"Eleutherakis-Papaiakovou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Despina","family":"Fotiou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vassiliki","family":"Spiliopoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Gavriatopoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachin","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Istvan","family":"Majer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christos","family":"Boukis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andriani","family":"Fetani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meletios A.","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evangelos","family":"Terpos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.clml.2024.03.003_bib0001","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/bjh.16213","article-title":"Pomalidomide plus low-dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure","volume":"188","author":"Siegel","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2024.03.003_bib0002","article-title":"Multiple myeloma: an overview of management","volume":"13","author":"Bird","year":"2019","journal-title":"Palliat Care Soc Pract"},{"issue":"4","key":"10.1016\/j.clml.2024.03.003_bib0003","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41408-019-0200-1","article-title":"Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide","volume":"9","author":"Moreau","year":"2019","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1016\/j.clml.2024.03.003_bib0004","first-page":"e528","article-title":"Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"5","author":"Dimopoulos","year":"2021","journal-title":"Hemasphere"},{"issue":"3","key":"10.1016\/j.clml.2024.03.003_bib0005","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/S1470-2045(20)30756-7","article-title":"Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group","volume":"22","author":"Moreau","year":"2021","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.clml.2024.03.003_bib0006","first-page":"430","article-title":"Current frontline treatment of multiple myeloma","volume":"36","author":"Holstein","year":"2022","journal-title":"Oncology (Williston Park)"},{"issue":"4","key":"10.1016\/j.clml.2024.03.003_bib0007","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41408-019-0205-9","article-title":"Current status of autologous stem cell transplantation for multiple myeloma","volume":"9","author":"Al Hamed","year":"2019","journal-title":"Blood Cancer J"},{"issue":"12","key":"10.1016\/j.clml.2024.03.003_bib0008","doi-asserted-by":"crossref","first-page":"e874","DOI":"10.1016\/S2352-3026(20)30356-2","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial","volume":"7","author":"Roussel","year":"2020","journal-title":"Lancet Haematol"},{"issue":"8","key":"10.1016\/j.clml.2024.03.003_bib0009","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1007\/s00277-020-04023-4","article-title":"The clinical management of lenalidomide-based therapy in patients with newly diagnosed multiple myeloma","volume":"99","author":"Merz","year":"2020","journal-title":"Ann Hematol"},{"issue":"12","key":"10.1016\/j.clml.2024.03.003_bib0010","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.6004\/jnccn.2020.0057","article-title":"Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"18","author":"Kumar","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"issue":"10","key":"10.1016\/j.clml.2024.03.003_bib0011","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa1402551","article-title":"Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma","volume":"371","author":"Benboubker","year":"2014","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.clml.2024.03.003_bib0012","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1038\/s41375-020-0711-6","article-title":"Daratumumab plus lenalidomide and dexamethasone in relapsed\/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study","volume":"34","author":"Bahlis","year":"2020","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.clml.2024.03.003_bib0013","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","article-title":"Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial","volume":"22","author":"Facon","year":"2021","journal-title":"Lancet Oncol"},{"issue":"18","key":"10.1016\/j.clml.2024.03.003_bib0014","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","article-title":"Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1","volume":"117","author":"Rajkumar","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2024.03.003_bib0015","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/ejh.13439","article-title":"Real-world treatment patterns and outcomes in non-transplant newly diagnosed multiple Myeloma in France, Germany, Italy, and the United Kingdom","volume":"105","author":"Mohty","year":"2020","journal-title":"Eur J Haematol"},{"issue":"Suppl","key":"10.1016\/j.clml.2024.03.003_bib0016","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/01.HS9.0000829632.52535.d2","article-title":"Evolution of multiple myeloma treatment patterns from 2015 through 2019: real-world evidence from a European database study","volume":"6","author":"Rocafiguera AOS","year":"2022","journal-title":"Hemasphere"},{"key":"10.1016\/j.clml.2024.03.003_bib0017","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.643490","article-title":"Treatment of lenalidomide exposed or refractory multiple myeloma: network meta-analysis of lenalidomide-sparing regimens","volume":"11","author":"Botta","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.clml.2024.03.003_bib0018","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.703233","article-title":"Defining unmet need following lenalidomide refractoriness: real-world evidence of outcomes in patients with multiple myeloma","volume":"11","author":"Lecat","year":"2021","journal-title":"Front Oncol"},{"issue":"7","key":"10.1016\/j.clml.2024.03.003_bib0019","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1007\/s00277-021-04522-y","article-title":"Survival and treatment patterns of patients with relapsed or refractory multiple myeloma in France - a cohort study using the French National Healthcare database (SNDS)","volume":"100","author":"Touzeau","year":"2021","journal-title":"Ann Hematol"},{"issue":"7","key":"10.1016\/j.clml.2024.03.003_bib0020","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1080\/17474086.2016.1195254","article-title":"Real-world treatment patterns and associated progression-free survival in relapsed\/refractory multiple myeloma among US community oncology practices","volume":"9","author":"Jagannath","year":"2016","journal-title":"Expert Rev Hematol"},{"issue":"6","key":"10.1016\/j.clml.2024.03.003_bib0021","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1470-2045(19)30152-4","article-title":"Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial","volume":"20","author":"Richardson","year":"2019","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.clml.2024.03.003_bib0022","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1038\/s41375-020-01021-3","article-title":"Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse","volume":"35","author":"Dimopoulos","year":"2021","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.clml.2024.03.003_bib0023","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study","volume":"17","author":"Dimopoulos","year":"2016","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.clml.2024.03.003_bib0024","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.clml.2019.09.623","article-title":"Daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in patients with previously treated multiple myeloma: three-year follow-up of CASTOR","volume":"20","author":"Mateos","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10245","key":"10.1016\/j.clml.2024.03.003_bib0025","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0140-6736(20)30734-0","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study","volume":"396","author":"Dimopoulos","year":"2020","journal-title":"Lancet"},{"issue":"10214","key":"10.1016\/j.clml.2024.03.003_bib0026","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study","volume":"394","author":"Attal","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.clml.2024.03.003_bib0027","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3390\/cancers15010155","article-title":"How to manage patients with lenalidomide-refractory multiple myeloma","volume":"15","author":"de Arriba de la Fuente","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.clml.2024.03.003_bib0028","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.clml.2024.03.003_bib0029","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1182\/bloodadvances.2019000539","article-title":"Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide\/dexamethasone","volume":"3","author":"Kastritis","year":"2019","journal-title":"Blood Adv"},{"issue":"12","key":"10.1016\/j.clml.2024.03.003_bib0030","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1038\/s41375-020-0813-1","article-title":"Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment","volume":"34","author":"Siegel","year":"2020","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.clml.2024.03.003_bib0031","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1182\/blood-2017-10-809293","article-title":"The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents","volume":"131","author":"Gavriatopoulou","year":"2018","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2024.03.003_bib0032","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","article-title":"Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial","volume":"22","author":"Dimopoulos","year":"2021","journal-title":"Lancet Oncol"},{"issue":"21","key":"10.1016\/j.clml.2024.03.003_bib0033","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3390\/cancers14215311","article-title":"Real-world use and effectiveness of carfilzomib plus dexamethasone in relapsed\/refractory multiple myeloma in Europe","volume":"14","author":"Terpos","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.clml.2024.03.003_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2020.07.2432","article-title":"The impact of missing\/incomplete data in real-world data studies","volume":"108","author":"Yang","year":"2020","journal-title":"Int J Radiat Oncol, Biol, Phys"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024001101?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024001101?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T21:21:17Z","timestamp":1718745677000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265024001101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S2152265024001101"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.03.003","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characteristics and Outcomes of Patients With Relapsed\/Refractory Multiple Myeloma After Exposure to Lenalidomide in First Line of Therapy: A Single Center Database Review in Greece","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}